Mitomycin c for Bladder Cancer

"This trial is presently closed to patient recruitment. It was initially posted on December 5th 2018 and the most recent edit took place October 31st 2022. If you are searching for a different study, there exist 2515 studies actively enrolling patients with carcinoma and 40 trials recruiting participants taking Mitomycin c medications."

"Clinicaltrials.gov reports that the given trial, first posted on December 5th 2018, is not presently accepting candidates. Nonetheless, there are currently 2555 other studies actively recruiting participants."

"As of today, there are 40 active studies involving Mitomycin c with 10 in their terminal stage. While a handful of these clinical trials take place in Bethesda, Maryland, the drug can be studied at 2029 locations globally."

"This clinical trial is enrolling 29 individuals diagnosed with carcinoma, ranging between 18 to 99 years of age. All potential candidates must adhere to the following criteria: diagnosis of urothelial carcinoma through radiographic, pathologic or cytological findings; Eastern Cooperative Oncology Group (ECOG) performance status grade 0-2; written consent and compliance with all study related procedures; for women of childbearing potential an adequate contraception method must be employed prior to and at least three months after mitomycin C instillation in order to avoid pregnancy risk factors; males are obliged to use contraceptive methods if female partners are under consideration for conception"

"Mitomycin c has been known to efficiently combat cervical cancers and can provide relief from other illnesses, such as glaucoma, mesotheliomas, and low-grade upper tract urothelial cancer (lg-utuc)."

"This trial only accepts applicants between 18 and 99 years old. Separately, there are 77 trials for young adults under the age of 18 and 2533 studies open to those above 65."

"Data from Phase 2 clinical trials suggests Mitomycin c may be relatively safe, so it was assigned a score of 2. Unfortunately, there is yet to be any data that supports its efficacy."